- Document Number:
20190177783
- Appl. No:
16/325023
- Application Filed:
August 07, 2017
- نبذة مختصرة :
Provided are vesicles derived from the genus Bacillus bacteria and a use thereof. Further, the vesicles are significantly reduced in samples of patients with cancers, such as liver cancer, bladder cancer, breast cancer, and ovarian cancer; inflammatory diseases, such as asthma and atopic dermatitis; or metabolic diseases, such as diabetes and cirrhosis, compared with normal persons, and the vesicles inhibited the secretion of inflammatory mediators by pathogenic vesicles, such as E. coli-derived vesicles, which are causative factors of inflammatory diseases, diabetes, and the like. Therefore, the vesicles derived from the genus Bacillus bacteria according to the subject matter can be advantageously used for the purpose of developing a diagnostic method for cancer, inflammatory diseases, and metabolic diseases, and a preventive or therapeutic composition therefor.
- Assignees:
MD HealthCare Inc. (Seoul, KR)
- Claim:
1. A method of providing information for diagnosis of cancer, a chronic inflammatory disease and a metabolic disease, comprising the following steps: (a) extracting DNA from vesicles isolated from samples obtained from a normal person and a subject patient; (b) obtaining a PCR product by performing PCR on the extracted DNA using a primer pair for detecting vesicles derived from bacteria of the genus Bacillus, present in a 16S rDNA sequence; and (c) determining as cancer, an inflammatory disease or a metabolic disease through quantitative analysis of the PCR product when a content of vesicles derived from bacteria of the genus Bacillus is lower than that of a normal person.
- Claim:
2. The method according to claim 1, wherein the cancer is liver cancer, bladder cancer, breast cancer, or ovarian cancer.
- Claim:
3. The method according to claim 1, wherein the inflammatory disease is asthma, chronic hepatitis, or atopic dermatitis.
- Claim:
4. The method according to claim 1, wherein the metabolic disease is diabetes or cirrhosis.
- Claim:
5. The method according to claim 1, wherein the sample obtained from the patient is a blood, urine or stool sample.
- Claim:
6. A method of providing information for diagnosis of diabetes, comprising the following steps: (a) extracting DNA from vesicles isolated from samples obtained from a normal person and a subject patient; (b) obtaining a PCR product by performing PCR on the extracted DNA using a primer pair for detecting vesicles derived from bacteria of the genus Escherichia, present in a 16S rDNA sequence; and (c) determining as diabetes through quantitative analysis of the PCR product when a content of vesicles derived from bacteria of the genus Escherichia is higher than that of a normal person.
- Claim:
7. The method according to claim 6, wherein the sample obtained from the patient is a blood, urine or stool sample.
- Claim:
8. A pharmaceutical composition for preventing or treating cancer, an inflammatory disease or a metabolic disease, comprising: vesicles derived from bacteria of the genus Bacillus as an active ingredient.
- Claim:
9. The pharmaceutical composition according to claim 8, wherein the cancer is liver cancer, bladder cancer, breast cancer, or ovarian cancer.
- Claim:
10. The pharmaceutical composition according to claim 8, wherein the inflammatory disease is asthma, chronic hepatitis or atopic dermatitis.
- Claim:
11. The pharmaceutical composition according to claim 8, wherein the metabolic disease is diabetes or cirrhosis.
- Claim:
12. The pharmaceutical composition according to claim 8, wherein the inflammatory disease is mediated by IL-6 or TNF-α.
- Claim:
13. The pharmaceutical composition according to claim 12, wherein the TNF-α-mediated inflammatory disease is hair loss, rheumatoid arthritis, or inflammatory enteritis.
- Claim:
14. The pharmaceutical composition according to claim 8, wherein the bacteria of the genus Bacillus are Bacillus subtilis.
- Claim:
15. The pharmaceutical composition according to claim 14, wherein the Bacillus subtilis is Bacillus subtilis natto.
- Claim:
16. The pharmaceutical composition according to claim 8, wherein the vesicles are isolated from a culture solution of the bacteria of the genus Bacillus.
- Claim:
17. The pharmaceutical composition according to claim 8, wherein the vesicles are isolated from food produced through culture by addition of the bacteria of the genus Bacillus.
- Claim:
18. The pharmaceutical composition according to claim 8, wherein the vesicles have an average diameter of 10 to 1000 nm.
- Claim:
19. A health functional food composition for alleviating cancer, an inflammatory disease or a metabolic disease, comprising: vesicles derived from bacteria of the genus Bacillus as an active ingredient.
- Claim:
20. The health functional food composition according to claim 19, wherein the cancer is selected from the group consisting of liver cancer, bladder cancer, breast cancer and ovarian cancer; the inflammatory disease is selected from the group consisting of asthma, chronic hepatitis, hair loss, rheumatoid arthritis, inflammatory enteritis and atopic dermatitis; and the metabolic disease is diabetes or cirrhosis.
- Claim:
21. The health functional food composition according to claim 19, wherein the vesicles are isolated from a culture solution of the bacteria of the genus Bacillus.
- Claim:
22. The health functional food composition according to claim 19, wherein the vesicles are isolated from food produced through culture by addition of the bacteria of the genus Bacillus.
- Claim:
23. The health functional food composition according to claim 19, wherein the bacteria of the genus Bacillus are Bacillus subtilis.
- Claim:
24. The health functional food composition according to claim 23, wherein the Bacillus subtilis is a Bacillus subtilis natto subtype.
- Claim:
25. An inhalant composition for preventing or treating an inflammatory disease, comprising: vesicles derived from bacteria of the genus Bacillus as an active ingredient.
- Claim:
26. The inhalant composition according to claim 25, wherein the bacteria of the genus Bacillus are Bacillus subtilis.
- Claim:
27. The inhalant composition according to claim 26, wherein the Bacillus subtilis is Bacillus subtilis natto.
- Claim:
28. A cosmetic composition for alleviating an inflammatory disease, comprising: vesicles derived from bacteria of the genus Bacillus as an active ingredient.
- Claim:
29. The cosmetic composition according to claim 28, wherein the inflammatory disease is selected from atopic dermatitis, hair loss, psoriasis, seborrheic dermatitis, and acne.
- Claim:
30. The cosmetic composition according to claim 28, wherein the bacteria of the genus Bacillus is Bacillus subtilis.
- Claim:
31. The cosmetic composition according to claim 30, wherein the Bacillus subtilis is Bacillus subtilis natto.
- Claim:
32. A method for preventing or treating cancer, an inflammatory disease or a metabolic disease, comprising: administering a pharmaceutical composition including vesicles derived from bacteria of the genus Bacillus as an active ingredient into a subject.
- Claim:
33. (canceled)
- Current International Class:
12; 12; 61; 61; 61; 61; 61; 61
- الرقم المعرف:
edspap.20190177783
Processing Request
No Comments.